Hepatitis B and C present clinicians with many challenges. This article reviews the epidemiology of hepatitis, along with its prevention through vaccination, diagnosis and treatment, especially in relation to approaching the exposure of healthcare workers to at-risk patients. The role of prevention, diagnosis and treatment with interferon agents and protease inhibitors is discussed. The treatment of hepatitis B and C is advancing and the intensivist should be aware of the options for healthcare workers exposed to its risk on the intensive care unit.
Introduction
Hepatitis is characterised by necrosis and inflammation of the liver and may result from infection with a variety of viruses. The clinical spectrum of viral hepatitis varies greatly from acute disease to, where infection persists, chronic hepatitis.
Hepatitis A, B and C viruses cause a global burden of disease. The load of disease due to hepatitis D (which exists as a co-pathogen with chronic hepatitis B (HBV) infection) and hepatitis E are still being evaluated and will not be discussed in this article. Complications of viral hepatitis include cirrhosis and hepatocellular carcinoma (HCC), which result in significant morbidity and mortality.
This poses many challenges to clinicians as it represents farreaching public health implications for the many millions of people that are asymptomatically infected worldwide.
Recent studies and research have analysed improved treatment options of HBV and hepatitis C (HCV) and this article will review new guidelines being introduced to incorporate these changes.
Epidemiology
An estimated 400 million people worldwide are chronically infected with hepatitis B virus, with approximately one million deaths annually from complications of chronic disease. A substantial proportion (up to 40%) of HBV-infected individuals go on to develop cirrhosis, fulminant hepatitis or hepatocellular carcinoma. 1 The prevalence of hepatitis B varies globally and the principal method of transmission of hepatitis B also varies. Sexual contact in high risk adults and intravenous drug users (IVDU) are responsible for most cases of transmission in low endemic areas (Europe, North America and Australasia) in contrast to high endemic areas (Sub-Saharan Africa and parts of Eastern Asia), where perinatal exposure and early childhood transmission are the main factors, 2 reflecting a much younger age majority in those affected in the developing world. HBV prevalence (hepatitis B surface antigen positive (HBsAgpositive)) within the UK is low, with the rates varying between 0.1-0.5%. 3 These infections are mainly acquired in adulthood through high risk behaviours and have declined compared to previous years. Although this reduction of prevalence of acute HBV in the UK shows the importance of surveillance and riskreduction initiatives (eg immunisation of high risk groups), the prevalence of chronic HBV is on the increase, mainly due to increased migration to the UK from areas of the world with high prevalence. Studies have shown that the majority of chronic HBV stems from immigration of HBV carriers rather than conversion from acute HBV infection. 4 Approximately 150 million people are infected with HCV. The majority have chronic infection, which accounts for approximately a quarter of all cases of HCC and cirrhosis. 5 HCV follows similar patterns of transmission and risk factors to HBV, in that the lower endemic regions have identified intravenous drug use as the predominant risk factor for acquiring the virus. Studies have shown that seropositive HCV infection is present in higher percentages of drug users than HBV. 6 In contrast, unsafe therapeutic injections and blood transfusions have been identified as the major risk factors in areas of higher endemicity. Prevalence of HCV (anti-HCV positive) within the UK remains low, with 0.4% of the population of England chronically infected and 216,000 in total within the UK. 7 The vast majority of infections are related to injecting drug users, and public health measures to combat the infection involve prevention, increasing awareness, increasing testing and diagnosis and encouraging those diagnosed into treatment and care.
Hepatitis B and C are both recognised global public health problems. The age of an individual when they acquire the virus influences the likelihood of developing chronic disease, with the probability decreasing with increasing age. Figures show that 90% of infected infants proceed to chronic hepatitis B 8 infection, whereas the majority of adults are able to clear the virus. This is likely to be due to the not-yet-fully developed immune system of an infant compared to an adult, resulting in an inability to eradicate the virus. In contrast, a higher percentage of adults go on to develop chronic hepatitis C infection than chronic hepatitis B infection. Due to their shared modes of transmission, co-infection with both viruses is a concern, especially in areas of high endemicity. 9 derived inactivated vaccine approved in 1981 was superseded by a genetically modified (recombinant DNA) version which is synthetically prepared to eliminate the risk of acquiring virus from the vaccine. Due to the increased risk of infection in childhood/infancy in developing countries, the hepatitis B vaccine has been incorporated into their vaccination programmes. 10 Currently in the UK, the vaccine is licensed only for those deemed at high risk of infection. This was the case in the US until 1991 when it was introduced to the immunisation schedule from birth. The main reason was that data in the US showed that up to a third of adults with HBV had no identifiable risk factors, and children/infants were three times more likely than adults to develop chronic disease. 11 Presently WHO recommends universal HBV vaccination for all infants. This has not yet been implemented in the UK. Current policy is that due to the relatively low incidence of chronic disease in the UK, the high cost of treatment and identifying patients most at risk, universal vaccinations are not felt to be cost-effective. 12 At present there is no vaccination for HCV. Although studies are ongoing to find vaccines to elicit sustained immunity against the virus, current analyses show that developing a vaccine that improves clearance of primary HCV rather than preventing the initial infection may be more feasible. This would still improve prevention against chronic infection, which is the cause of morbidity. 13 Ultimately, prevention of both HBV and HCV is difficult; active surveillance of at-risk groups by medical practitioners and increased public awareness of symptoms and signs of the disease and high risk behaviours that can increase transmission are important. This may lead to treatment at earlier stages of disease, which may decrease morbidity and mortality. Screening for chronic infection in high-risk populations of the UK is important in order to prompt referral as early as possible. Responsibility lies with GP practices, antenatal services, local community services and in-hospital staff to refer early and initiate screening virology in those thought to be at high risk of infection. These patients include migrant populations from high endemic areas, intravenous drug users, babies born to HBV/HVC positive mothers, pregnant mothers, homosexual men, those participating in unprotected sex, HIV-positive patients, prisoners, the care home population, those who have had a blood transfusion prior to 1991, and those found to have unexplained abnormal liver enzyme results. 14, 15 Once identified, serological tests are used to confirm or disprove disease status. In the UK these are HBsAg and anti-HCV (hepatitis C antibody) and will be discussed later.
Another group of at-risk individuals are healthcare workers who are exposed to bodily fluids of patients who are potentially infectious. Every clinical worker within the hospital setting should have an HBV vaccination course, but when exposed to potential infective patients through needle-stick injuries there is still potential for acquiring HBV in addition to other infections, including HCV and HIV.
The cost of these injuries in the context of work productivity and medical costs are significant, approximating $188.5 million in the US in 2004 with an estimated $650.00 cost of managing one post-exposure evaluation after HCV. In a national audit conducted in 2003, needlestick injuries accounted for 17% of accidents within the NHS with 40,000 reported incidents each year, just behind moving and handling misadventures (18%).
The risk of transmission following percutaneous injury from an HBV-, HCV-or HIV-infected patient is 1/3, 1/30 and 1/300 respectively. 16 Worldwide in 2000, there were 66,000 such cases of hepatitis B, 16,000 of hepatitis C and 1,000 cases of HIV. 17 The Health Protection Agency monitors occupational exposures and potential transmission of HBV/HCV and HIV from patients to healthcare workers through a national surveillance scheme, with data reported in the regularly updated 'Eye of the Needle' report. One of the main issues identified by these surveillance schemes is under-reporting of exposure incidents, with some studies quoting rates as high as 85% remaining unreported. Locally, hospital Trusts should ensure systems are in place for reporting all needlestick injuries to prevent exposure as much as possible through risk assessment processes. Failure to prevent needlestick injuries can put Trusts in breach of regulations and have resulted in fines and compensation packages to infected health workers.
The first step to preventing these injuries is to identify the most likely hazards. Sharps and needle injuries are highlighted as a key hazard. Acknowledging which workers are vulnerable is another important consideration. Clinical workers are not the only ones at risk; ancillary service workers may be injured by inappropriate use or disposal of sharps. Key measures to prevent exposure and injury include: -Regular education for healthcare workers about safe systems of work with sharps and bodily fluids -Free hepatitis B vaccination -Needle safety devices -Safe disposal containers -Provision of personal protection equipment (gloves and double gloving, gowns and eye shields) -Work practice (no needle re-sheathing, safe sharp containers, positioning containers at eye level and within arm' s reach, disposing of sharps immediately after use, sealing and discarding containers when 3/4 full) -Waterproof dressings for workers' cuts and grazes -Eliminate hazards where possible (eg remove sharps/ needles) -Adequate removal mechanisms (adequate numbers of accessible sharps' containers, sharp protection devices eg needles that retract or blunt after use). These measures should be part of each Trust' s regulations and be mandatory to educate health workers prior to commencement of their posts.
Following exposure, a confidential medical evaluation and follow-up is required, which involves: 1. First aid measures (thoroughly washing eyes or mouth with water, encouragement of free bleeding from punctured skin and washing with soap or chlorhexidine) 2. Identification and documentation of the source individual 3. Documentation of the time and date of exposure 4. Documentation of the route of exposure and type of fluid (eg percutaneous, mucocutaneous, bites, scratches) 5. Assessment of risk of transmission (percutaneous/ mucocutaneous) 6. Testing the source' s blood for HBV-, HCV-and HIVinfectivity (after gaining informed consent from the source by another member of staff) 7. Results of the source individual' s testing made available to the exposed employee 8. Employee' s blood collected and tested (HBV immune status) 9. Serum storage for employee (in the event of seroconversion, if the staff member was not infected at the time of the exposure, the infection would be occupationally acquired) 10. Counselling of the exposed employee 11. Post-exposure prophylaxis (HIV) OR hepatitis B immunoglobulin or booster (HBV) given if indicated.
In the case of exposure to blood known or suspected to be HBsAg positive, post-exposure prophylaxis (PEP) with HBV immunoglobulin or vaccine should be administered. Exposure to an unvaccinated employee should lead to an HBV vaccination course, regardless of the status of the source patient. In general, PEP is considered for any exposure in the workplace and is driven by the HBsAg status of the source and the vaccine response status of the exposed (see Table 1 for clarification).
There is no prophylaxis available for hepatitis C. The blood of the exposed staff member should be taken for storage and if the source has HCV, then the staff member is required to have a six-week HCV-RNA polymerase chain reaction (PCR) test, three-month HCV antibody with HCV-RNA PCR and then a six-month HCV antibody level to monitor for infection. 18
Diagnostic methods

Hepatitis B
The diagnosis of hepatitis B usually rests upon detection of HBsAg in serum. Following infection, this is the first marker to become detectable, two to eight weeks prior to biochemical evidence of liver damage or the onset of jaundice. Detection of HBsAg is used widely in screening, for example, in transfusion centres or during antenatal screening.
Next to appear are the markers of the virion, such as viral DNA along with soluble hepatitis B e-antigen (HBeAg).
Antibody to the core is detectable two to four weeks after the appearance of surface antigen and persists throughout life.
Clearance of the virus is marked by seroconversion with the disappearance of HBeAg and the appearance of anti-HBe antibodies. Finally HBsAg disappears and is replaced by antisurface antibody (anti-HBs). Identifying the phase of infection from various serological markers ( Table 2) is important to guide further testing (Figure 1 ) in order to determine suitability for treatment and likelihood of progressive disease.
HBV DNA PCR is widely available in virology specialist centres and can be used to evaluate the viral load. This has been shown to have prognostic value in the evaluation risk of cirrhosis and development of hepatocellular carcinoma in patients with chronic infection. It is also used to monitor antiviral therapy. Rarely, acute hepatitis B may be diagnosed during the period when HBsAg titres have declined below detectable levels and anti-HBs has not yet appeared. In this HBV status of exposed HBsAg positive source HBsAg negative source HBsAg unknown
Known responder Consider vaccine booster Consider vaccine booster
Consider vaccine booster (anti-HBs >10 mIU/mL)
Non-responder to vaccine
Consider vaccine booster and Consider vaccine booster. Same as HbsAg positive (anti-HBs <10 mIU/mL) HB-IG (HB immunoglobulin) dose No HB-IG management and second HB-IG dose at one month Non-immune: less than or HB-IG dose and an accelerated vaccine Course of vaccination Accelerated course of equal to one vaccine dose programme (0, 1 and 2 months) vaccination pre-exposure Non-immune: more than or
One dose vaccine and Finish vaccine course One dose vaccine equal to two vaccine doses second dose one month later pre-exposure Table 1 Post HBV exposure prophylaxis for healthcare professionals. scenario, known as the 'window period,' the diagnosis of acute HBV infection is made based on the presence of positive IgM anti-HBc titres. Most virology labs currently use commercially available HBsAg enzyme-linked immunoabsorbent assay (ELISA) tests, which have been shown to have high sensitivity (99%) and comparable specificity (95.5-99.4%). 19 Recent developments have postulated that nucleic acid amplification based tests (NATs) are more sensitive than ELISA techniques in detecting HBV, 20 with its potential use to identify infectious cases prior to seroconversion. NICE guidelines published in June 2013 21 recommend the following diagnostic pathway (see Figure 1 ) for suspected hepatitis B infection. Suspected cases should have hepatitis B surface antigen measured initially, then progress to measuring further serologic markers of HBV infection, liver biochemistry and imaging if this is detected. Referral to a specialist is recommended for further management of patients with chronic HBV infection.
Serological markers Result Phase of infection
Hepatitis C
HCV diagnosis is made through early antibody detection via ELISA methods. These can lack sensitivity and specificity in early infection. It is therefore recommended that HCV-RNA PCR is performed in patients when acute or new infection is suspected, as well as in immunosuppressed patients that may be unable to mount an antibody response, such as HIV patients.
In the UK, screening serology should be considered for all IVDUs, needle-stick injuries, blood donors, haemophiliacs/ other patients who have received blood/blood products prior to 1990, men who have sex with men, sex workers, sexual partners of HCV-positive patients, HIV-positive patients, alcoholics and ex-prisoners. 14 The sensitivity of ELISA methods for detection of HCV are comparable to HBV, with lower accuracies evident in those with HIV co-infection. 22 Additionally NATs are also being put forward for potential use in HCV diagnosis as supplementary confirmation following a positive anti-HCV screening test. 23
When to offer treatment for HBV
Following infection with HBV, a patient may either clear the infection or become chronically infected. Treatment is currently aimed at patients with chronic hepatitis B infection who have active disease and viral replication. No interventions have been proven to prevent progression to chronic hepatitis B once a person has been infected. The major aim of therapy for hepatitis B is to prevent progression of disease to cirrhosis, end-stage liver disease and HCC.
The NICE recommendations 21 about when to start treatment include assessment of liver disease and the serological evidence of infection (Tables 3 and 4) and offers specific guidance for treatment (Figures 2 and 3) . The use of transient elastography (fibroscan) as part of the diagnostic workup is relatively new. This involves measuring the amplitude of an USS wave as it passes thorough the hepatic parenchyma, with its speed correlating to tissue stiffness, which in turn correlates with the degree of fibrosis. Expressed as kilopascals (kPa), the cutoffs are >7.0 kPa for significant fibrosis (graded F2-F4) or <6 kPa for no fibrosis (F0-F1). Measurements over 11 kPa signify cirrhosis. The ability to effectively measure the degree of fibrosis helps to predict the likelihood of response to interferon-based therapy, since advanced stages of fibrosis (F3 or F4) generally have a lower response rate. This allows deferment of treatment if little fibrosis progression has occurred and identifies those who are likely to develop cirrhosis so as to screen them for the development of HCC. 24 Magnetic resonance elastography is available in the US, and offers higher sensitivity and specificity than USS techniques in identifying significant fibrosis and cirrhosis. 25 The hope is to use these techniques to prevent the potentially traumatic process of obtaining a biopsy to guide the decision to treat.
It is not currently recommended that children undergo USS elastography in the UK for determination of suitability for treatment, with the consensus view presently to biopsy if the HBV DNA is over 2,000 IU/mL with abnormal ALT results.
Newly referred HBV patient into specialist centre
As a whole, providing treatment to these patients requires specialist supervision and is done with careful consideration of the severity of disease and on an individual patient basis. Even if serological and pathological evidence suggests that treatment is the best option, detailed discussions with the specialist, the patient and the parents where children are concerned, need to take place. These discussions need to include all the up-to-date treatment options, adverse effects and long-term prognosis before making a final decision about starting treatment.
A new age for treatment
The aim of treatment for HBV is to enhance the patient' s immune response. There are a number of limitations to treatment that include pre-treatment immune status, cost, tolerance, resistance and treatment failure. The current thoughts behind research into improved therapies are to establish better mono-therapies of immune regulation and possible combination treatments with antivirals in refractory cases.
Interferon (IFN) alpha was the first immunological agent introduced for HBV; however increasing cost, tolerance, the need for a high level of initial immunity for better results (therefore earlier commencement) and resistance 26 led to the development of pegylated IFN (PEG-IFN) therapy, which has shown to improve HBeAg loss, suppress HBV DNA longer and normalise ALT more quickly than conventional IFN.
Newer antivirals to treat chronic hepatitis B were introduced to replace previous agents such as lamivudine and adefovir. A systematic review of published randomised controlled trials of drugs for hepatitis B have shown tenofovir and entecavir to be the most potent agents for HBeAg-positive and negative disease in the first year of treatment in therapy-naive patients. 27 Entecavir shows promise in decompensated HBV cirrhosis, and the introduction of these agents into treatment regimes for HBV-infected patients has been a major stride forward. The recent NICE guidelines 21 have suggested the use of PEG-IFN as first line therapy in the UK, with tenofir and entecavir reserved as second line therapies in treatment failures or relapses (Figures 2 and 3) . They follow the American guidelines which also suggest PEG-IFN, tenofovir and entecavir as preferred options. 28 
Hepatitis C treatment
HCV-positive results from high risk subsets of the population should be considered for treatment. The decision to treat is based on viral genotypes known to respond to therapy, patient preference with the likelihood of adherence, the age of the patient, lack of contraindications which include severe co-morbidities and biopsy findings 29 taken into account. The degree of fibrosis on biopsy is the main indicator that drives treatment and the decision to biopsy is through identifying virological genotype, hepatic biochemistry and other functional tests (eg platelets) and at times ultrasonography. There are multiple validated staging systems available to assess the degree of fibrosis with the presence of advanced or bridging fibrosis indications for treatment. Patients with HCV-related decompensated liver cirrhosis should be considered for transplantation rather than drug treatment.
There is evidence showing the benefit of treating acute hepatitis C with antiviral therapy early, due to the high chance of chronic disease and complications if left untreated. 30 There are no current guidelines suggesting which regime to use but pegylated interferon or standard interferon with scope to add in ribavirin if required, is widely accepted.
Guidelines worldwide had advised combination therapy of pegylated interferon alpha and ribavirin for treatment of chronic hepatitis C, of the genotype 2,3 or 4. 29, 31 Varying doses are required for different genotypes of the virus but the same combination is recommended.
The driving force behind the combination regimes of immunotherapy with antiviral agents stems from comparative analysis that showed in patients with chronic hepatitis C, once weekly peginterferon alpha and ribavirin were tolerated better and produced significantly higher rates of sustained viral response (SVR) as compared with conventional interferon alpha plus ribavirin or peginterferon alpha alone. 32 For treatment of genotype 1 however, recommendations suggest the addition of a protease inhibitor to the PEG-IFN and ribavirin combination. This triple therapy is widely used as first line treatment, with the protease inhibitor of choice being teleprevir then boceprevir. In combination with PEG-IFN/ribavirin they have been found to be significantly effective. 33 The significantly higher sustained viral response seen in this triple combination treatment will hopefully encourage patients to take treatment and benefit public health by reducing transmission. These outcomes have been incorporated into UK guidelines for HCV management.
The world of hepatitis C treatment is evolving and with the discovery of protease inhibitors in 2011 for use against the virus, promising research is now emerging for use of antivirals. The future of an interferon-free regime for HCV is a possibility and would negate the harmful side effects encountered with these drugs, including myelosuppression, nephrotoxicity, neurological and psychological effects. Recent trials have shown promise for antiviral agents acting directly against the virus, with the future aim of having a once-daily interferon-free regimen. Challenges include preventing resistance by developing new drugs, optimising duration of treatment and finding a regimen that incorporates all viral genotypes. 34
Conclusion
Hepatitis B and C present global health burdens associated with significant morbidity. Their high risk of transmission requires that clinicians need to be vigilant and screen those they deem to be infectious. Active surveillance is key to early identification and treatment of cases, not only to prevent disease progression in infected individuals but also to prevent transmission to the general population.
The future is looking brighter in terms of the development of new therapeutic agents. To produce a regimen with improved efficacy, improved cost and freedom from severe toxicity is something to strive towards and with recent developments in treatments for both HBV and HCV, this can be a realistic aim.
